Date: October 28, 2014
Time: All-day
Newly established clinical biomarkers including the AA to EPA ratio highlight the extent to which inflammation underlies chronic illnesses. Dr Bailey presents compelling evidence for an EPA-based fatty acid approach to resolving inflammation that, when applied together with Igennus’ new Opti-O-3 blood spot fatty acid biomarker test, provides an effective nutrition management strategy for health practitioners treating a variety of conditions. Learn how this straightforward blood spot method can add value to your clinical approach by identifying your clients’ individual omega-3 requirements needed to manage biomarkers that correlate with long-term health and reduced disease risk.